Drawing for MLI RX ADVANTAGE

USPTO serial 75465816

MLI RX ADVANTAGE

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
LOBO, DEBORAH E
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MLI RX ADVANTAGE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ELLIOTT C BANKENDORF

Elliott C. Bankendorf Partridge IP Law P.C.Suite 720321 N. Clark StreetCHICAGO, IL 60654

Goods and services

ClassDescriptionStatusFirst use
036prepaid financing, underwriting and administration of medical, hospital, prescription, pharmacy and related health care servicesABANDONED—
042comprehensive prescription and pharmacy programs, including those rendered in connection with a health maintenance organization or other managed care organizationABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 20, 2013TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 10, 1998ABN1ABANDONMENT - EXPRESS MAILED—
Nov 30, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 1998DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance